Holen Sie sich die Stockscreener-App
78.40
0.30%
-0.6967
Schlusskurs vom Vortag:
$79.10
Offen:
$78.96
24-Stunden-Volumen:
211.55K
Relative Volume:
0.34
Marktkapitalisierung:
$3.50B
Einnahmen:
$156.12M
Nettoeinkommen (Verlust:
$-395.33M
KGV:
-7.5564
EPS:
-10.3758
Netto-Cashflow:
$-292.33M
1W Leistung:
-2.11%
1M Leistung:
+13.50%
6M Leistung:
+58.29%
1J Leistung:
+110.13%
1-Tages-Spanne:
$77.60
$81.17
1-Wochen-Bereich:
$77.60
$82.61
52-Wochen-Spanne:
$35.39
$118.84
Grail Inc Stock (GRAL) Company Profile
Firmenname
Grail Inc
Sektor
Branche
Telefon
(833) 694-2553
Adresse
1525 O'BRIEN DRIVE, MENLO PARK
Compare GRAL vs TMO, DHR, NTRA, IQV, IDXX
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
GRAL
Grail Inc
|
78.37 | 3.53B | 156.12M | -395.33M | -292.33M | -10.38 |
TMO
Thermo Fisher Scientific Inc
|
602.90 | 222.97B | 45.20B | 6.87B | 6.75B | 18.19 |
DHR
Danaher Corp
|
202.98 | 144.27B | 24.78B | 3.68B | 5.29B | 5.1743 |
NTRA
Natera Inc
|
324.74 | 46.72B | 2.50B | -226.32M | 71.51M | -1.6412 |
IQV
Iqvia Holdings Inc
|
256.49 | 42.67B | 16.63B | 1.39B | 2.12B | 8.0674 |
IDXX
Idexx Laboratories Inc
|
518.88 | 40.98B | 4.45B | 1.10B | 1.06B | 13.59 |
Grail Inc Stock (GRAL) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2026-04-10 | Eingeleitet | Mizuho | Neutral |
| 2026-03-18 | Hochstufung | TD Cowen | Hold → Buy |
| 2026-02-19 | Eingeleitet | TD Cowen | Hold |
| 2026-02-17 | Eingeleitet | Robert W. Baird | Outperform |
| 2025-12-02 | Fortgesetzt | Morgan Stanley | Equal-Weight |
| 2025-11-12 | Hochstufung | Guggenheim | Neutral → Buy |
| 2025-04-21 | Eingeleitet | Canaccord Genuity | Buy |
| 2024-11-27 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2024-11-15 | Eingeleitet | Wolfe Research | Peer Perform |
| 2024-10-17 | Eingeleitet | Guggenheim | Neutral |
Alle ansehen
Grail Inc Aktie (GRAL) Neueste Nachrichten
Grail CFO Aaron Freidin Sells 7,900 Shares for $672,000 - Yahoo Finance
GRAL INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announc - The National Law Review
Grail Stock Jumps in August as FDA Schedules a Key Meeting for its Galleri Cancer Test - Yahoo Finance
GRAIL Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - PR Newswire
Have Insiders Sold GRAIL Shares Recently? - simplywall.st
GRAIL grants 55,867 RSUs to 59 new employees as hiring incentive under Nasdaq rules. - Pluang
GRAIL (GRAL) Institutional Ownership 2026 $GRAL - MarketBeat
Grail CFO Aaron Freidin sells $671,579 in company stock By Investing.com - Investing.com South Africa
Grail CFO Aaron Freidin sells $671,579 in company stock - Investing.com
Grail CEO Joshua Ofman sells $425,098 in company stock - Investing.com
GRAIL CFO sells 7,900 shares at $85.01 avg - Stock Titan
GRAIL to Present at Morgan Stanley's 24th Annual Global Healthcare Conference - TradingView
GRAIL (NASDAQ: GRAL) insider Joshua Ofman plans to sell 10,000 shares - Stock Titan
Why Is GRAL Stock Down Today? Analysts Lower Targets After UK Trial Setback But Call Selloff Overdone - Stocktwits
Biotech Frenzy Sends GRAIL Soaring Ahead of FDA Showdown - TipRanks
Investigation announced for Long-Term Investors in shares of GRAIL, Inc. (NASDAQ: GRAL) over potential Wrongdoing - openPR.com
GRAIL (GRAL) Earnings Report: Profit Per Share Surpasses Its Benchmark in the Current Update; Post-Report: The Market Price Advances 6.19% in Latest TradingGross Profit Margin - dars.gov.et
Grail Stock Rockets Back As Traders Buy The Dip - TipRanks
GRAIL (GRAL), What Is Behind The Fresh Attention On The Stock? - simplywall.st
Why Silver Grail Resources Ltd stock is skyrocketing today - Wealth Awesome
Russell Investments Group Ltd. Has $1.94 Million Holdings in GRAIL, Inc. $GRAL - MarketBeat
How (GRAL) Movements Inform Risk Allocation Models - news.stocktradersdaily.com
GRAL Q2 2026 Earnings: Narrower-Than-Expected Loss Highlights Cost DisciplineEarnings Season Review - Vinanet
GRAIL Highlights Galleri Growth Ahead of Key FDA Advisory Meeting - MarketBeat
GRAL|Grail Inc|Price:68.180|Chg%:-0.760 - TradingKey
Farallon group discloses 9.6% GRAIL, Inc. (GRAL) holding in Schedule 13G/A - Stock Titan
GRAIL Q2 2026 Earnings: EPS Beats Estimates by 5.37% Amid Muted Stock ReactionEarnings Acceleration Picks - Vinanet
GRAIL Inc. (GRAL) Edges Lower 0.84% as Shares Hold Above $64.94 SupportValue Area Low - Vinanet
GRAIL2026 Funding Rounds & List of Investors - Tracxn
GRAIL, Inc. (NASDAQ:GRAL) Given Consensus Recommendation of "Hold" by Brokerages - MarketBeat
Bank of America Corp DE Purchases 205,611 Shares of GRAIL, Inc. $GRAL - MarketBeat
GRAIL: Looking Beyond The NHS-Galleri Headline (NASDAQ:GRAL) - Seeking Alpha
GRAIL (NASDAQ:GRAL) Stock Price Down 6.3%What's Next? - MarketBeat
Cancer Detection Firm Nears FDA Breakthrough Blood-Test Review - Streetwise Reports
GRAIL Galleri Test Heads to FDA Panel for Multi-Cancer Screening Review - Streetwise Reports
GRAIL INC : PIPER SANDLER RAISES TARGET PRICE TO $74 FROM $56 - webull.com
FDA panel to review GRAIL’s Galleri multi-cancer blood test in September - Mugglehead Investment Magazine
GRAIL (NASDAQ:GRAL) Trading Up 7.6%Time to Buy? - marketbeat.com
FDA Panel Schedules to Evaluate GRAIL Premarket Approval Application for Multi-Cancer Early Detection Test - Benzinga
FDA panel to weigh Grail’s Galleri test - STAT
GRAIL’s Galleri becomes first multi-cancer detection test headed to US FDA advisory panel - AllSci
Renaissance Technologies LLC Sells 30,100 Shares of GRAIL, Inc. $GRAL - MarketBeat
Illumina Seeks Court Approval of GRAIL Settlement - The Globe and Mail
GRAIL Inc Revenue Breakdown – LSX:A40F8M - TradingView
Is GRAIL (GRAL) Fairly Valued Following Galleri Adoption Growth And The FDA Panel Date? - Yahoo Finance
US FDA to hold advisory meeting to review Grail’s multi-cancer test - WTVB
US FDA to hold advisory meeting to review Grail's multi-cancer test - Reuters
FDA to hold adcomm for Grail cancer test that failed in large, randomized trial - Endpoints News
FDA panel to review GRAIL’s cancer detection test on Sept. 23 - Investing.com
GRAIL Insiders Sold US$29m Of Shares Suggesting Hesitancy - Moomoo
GRAIL to face FDA AdCom for Galleri cancer test (GRAL:NASDAQ) - Seeking Alpha
Finanzdaten der Grail Inc-Aktie (GRAL)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.07%
0.87%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):